Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Core Insights - Caribou Biosciences, Inc. is presenting clinical data on its allogeneic CAR-T cell therapies, vispa-cel and CB-011, at the 2026 Tandem Meetings, highlighting their potential in treating relapsed or refractory hematologic malignancies [1][2][3] Group 1: Clinical Trials and Data - The ANTLER phase 1 clinical trial for vispa-cel shows outcomes comparable to autologous CAR-T therapies in patients with relapsed/refractory B cell non-Hodgkin lymphoma [5][6] - The CaMMouflage phase 1 clinical trial for CB-011 demonstrates a correlation between CAR-T cell expansion and durable responses in patients with relapsed/refractory multiple myeloma [5][8] - A total of 84 patients have been treated in the ANTLER trial, with a recommended phase 2 dose of 80x10^6 CAR-T cells selected [6] Group 2: Product Information - Vispa-cel is the first allogeneic CAR-T cell therapy with a PD-1 knockout, aimed at enhancing CAR-T cell activity by reducing exhaustion [4][9] - CB-011 employs an immune cloaking strategy with a B2M knockout and a B2M–HLA-E fusion protein to mitigate immune rejection [7][9] - Both therapies have received Fast Track and Orphan Drug designations from the FDA, indicating their potential to address unmet medical needs [4][7] Group 3: Company Overview - Caribou Biosciences focuses on developing transformative therapies using its CRISPR genome-editing platform, aiming to improve access to cellular therapies for patients with severe diseases [9] - The company emphasizes the potential of its off-the-shelf CAR-T cell therapies to provide rapid treatment options for patients with hematologic malignancies [9]